This company listing is no longer active
G1 Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
G1 Therapeutics has a total shareholder equity of $24.6M and total debt of $44.3M, which brings its debt-to-equity ratio to 180.2%. Its total assets and total liabilities are $98.7M and $74.1M respectively.
Key information
180.2%
Debt to equity ratio
US$44.32m
Debt
| Interest coverage ratio | n/a |
| Cash | US$60.73m |
| Equity | US$24.59m |
| Total liabilities | US$74.10m |
| Total assets | US$98.69m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: G1H's short term assets ($92.9M) exceed its short term liabilities ($37.5M).
Long Term Liabilities: G1H's short term assets ($92.9M) exceed its long term liabilities ($36.6M).
Debt to Equity History and Analysis
Debt Level: G1H has more cash than its total debt.
Reducing Debt: G1H's debt to equity ratio has increased from 0% to 180.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G1H has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if G1H has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.